Hiru Corp. (PINK:HIRU) focuses on veterinary products for the Chinese agricultural market through its Shuangshi AHP subsidiary. The company also operates MindUp Bioresearch, an RD lab focusing on cancer therapy, and the latest news comes from there.
HIRU is still bearing the Caveat Emptor on OTC Markets, but yesterday, after a PR late in the session it managed to generate a 106 million shares volume and moved up 33.33% closing at $0.0004.[BANNER]
The announcement that triggered the surge was about the activities of HIRU’s MindUp subsidiary. The company revealed some of their results in testing the effect of two purine analogs sulfinosine on cell growth inhibition.
The topic is exciting but the PR itself doesn’t give any definitive information on how those results may matter for HIRU.
Nevertheless, it obviously stirred some attention, and it may have some effect today too, coupled with HIRU’s appearance in some paid promotional newsletters. The direction of the effect is not clear, because HIRU has chosen to not provide any financial information since March.
Investing in such “dark” companies is risky. And the obvious reluctance of HIRU to abide by the rules, doesn’t put investors in the best of positions.
